Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
AB STR A CT
Objectives: To develop a multistate model and an algorithm for the prevalence of patients waiting to initiate treatment, patients with
calculating long-term adherence to medication among patients with supply to implement the prescribed dosing regimen, patients not
a chronic disease. Methods: We propose definitions of the different accepting treatment, and patients discontinuing treatment varies
states of waiting, persistence, with sufficient supply to implement the over time. Conclusions: The proposed multistate model and algo-
prescribed dosing regimen, gaps, nonpersistence, and nonacceptance rithm can easily be translated and used for the calculation of
and an algorithm for transitions between states to describe long-term adherence to medication in any chronic disease. The model and
adherence to medication treatment. The model and algorithm are algorithm take time into account, and thus, changes in incidence
operationalized for use in a case with a retrospective cohort of rates and prevalence of the different states over time can be estimated
patients with type 2 diabetes mellitus, with access to records of on several time scales (calendar time, age of the patient, and time
since indication for medication).
prescribed drugs from a Danish diabetes research hospital and records
Keywords: acceptance, adherence to medication, diabetes mellitus,
of filled prescriptions at Danish pharmacies from the Danish Health
implementation, multistate model, persistence.
and Medicines Authority. Results: Calculations of long-term adher-
ence to medication are shown for patients with type 2 diabetes Copyright & 2014, International Society for Pharmacoeconomics and
mellitus on metformin and/or simvastatin. The study shows how Outcomes Research (ISPOR). Published by Elsevier Inc.
* Address correspondence to: Majken Linnemann Jensen, Steno Diabetes Center A/S, Niels Steensens Vej 1, (NLD2.06-MLiJ), DK-2820
Gentofte, Denmark.
E-mail: MLiJ@steno.dk.
1098-3015/$36.00 – see front matter Copyright & 2014, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.jval.2013.11.014
VALUE IN HEALTH 17 (2014) 266–274 267
of event is of interest: when the patient is prescribed with the Every person in Denmark is identified by a unique identity
drugs for the first time, when he or she initiates treatment, when number (the Danish Civil Registration number), which is used for
he or she runs out of supply, or when he or she or the prescribing linkage of registers in this analysis.
doctor discontinues the treatment. We set up a multistate model
to describe the events of interest allowing the same type of event
to occur more than once [19].
Along with development of the multistate model, rules for an Methods
algorithm describing how and when a patient moves between the
different states must be defined. Patients enter the study on the day of the first written prescrip-
Type 2 diabetes mellitus (T2DM) has been chosen as the tion at Steno after January 1, 1998, for the drugs in question. End
case of a chronic illness because it is the main focus of of follow-up per patient per type of drug is the earliest of date of
the research team, and we have access to extensive data. T2DM death, the last date of referral of the patient from Steno to a
is a complex metabolic disorder and prevalent in both industrial- physician or another specialist unit before December 31, 2009, or
ized and developing countries [20]. Guidelines [21] for the treat- December 31, 2009.
ment of T2DM recommend long-term multifactorial medication The drugs are classified according to WHO’s ATC codes at
therapy for hyperglycemia, hypertension, hypercholesterolemia, level 5 as of January 1, 2010. Amounts of prescribed and
and anticoagulation to prevent/postpone diabetes complications. purchased drugs are transformed into units of DDD by using
Metformin (ATC code: A10BA02, recommended as first-choice WHO’s DDD values as of January 1, 2010.
blood glucose–lowering medication in T2DM [21]) and simvasta- For the definition of this multistate model and algorithm,
tin (ATC code: C10AA01, recommended as first choice for adherence to medication is restricted to prescriptions of drugs in
dyslipidemia in T2DM in Denmark [22]) were chosen as which the prescribed daily dose is known as well as the amount
case drugs. ATC codes refer to WHO’s Anatomical Therapeutic of the drug being filled. Drugs prescribed to be used “as needed”
Chemical classification system codes [23]. The multistate (e.g., insulin) and over-the-counter drugs can therefore not be
model and the corresponding estimation algorithm can be used covered by this model and algorithm.
for any type of long-term medication used by patients with For each type of drug for each patient, records with prescribed
a chronic disease, for example, human immunodeficiency daily dose including starting and ending dates are extracted from
virus-positive patients, cancer patients, or organ transplanted Steno’s Electronic Medical Record (EMR). All records on Rx from
patients. the RMPS are sorted by patient, by type of medicine, and by
Thus, the aim of the current study was to develop a multistate day of purchase in ascending order and handled one by one
model to be used as a tool to describe and measure long-term consecutively.
adherence to treatment for patients with a chronic disease on Duration of the first Rx starts on the day of purchase and lasts
lifelong medication. The model can cover either one drug at the until the amount has been spent according to the daily prescribed
time (as in this study) or a group of drugs. dose. The daily prescribed dose can in theory vary every day. This
information is used to compute the duration of a given Rx. If
subsequent prescriptions are filled within the previous Rx’s
Case Material duration time, the duration of these will be pasted to the end of
the previous Rx. Adjustment for waste of the drug is not included.
Any oversupply is capped only at the very end of the follow-up
Study Population
period.
A cohort of patients with T2DM from the Danish diabetes The medication process, shown graphically in Figure 1 and
research hospital Steno Diabetes Center (Steno), a specialized concepts detailed in Figure 2, starts with the first written
diabetes tertiary referral hospital for patients with both type 1 prescription of a daily dose of a given drug to the patient by the
diabetes mellitus and T2DM, was used. A total of 4322 patients physician. The patient can adhere to the timing and dosage of
with T2DM with at least one written prescription of either taking the drug only if he or she initiates treatment by filling the
metformin or simvastatin and enrolment at Steno during the prescription and hereafter refills the prescription with a fre-
period 1998 to 2009 were included. quency that allows for a sufficient supply of the drug. If the
patient runs out of supply before refilling the next prescription,
Daily Doses Prescribed by the Physician we say that a gap occurs. In the absence of a Medication Event
Since 1998, the physicians at Steno have made electronic regis- Monitoring System in register-based studies, we are forced to
trations of their recommendations of medication to the patients. assume that medication corresponding to the prescribed daily
The recommendations are recorded for each drug identified by dose is taken every day until the available supply has been used.
the ATC code with a starting date and a daily dose. Cessation of a A scenario in which a patient from time to time skips days to
recommendation is recorded with an ending date. These recom- extend supply—perhaps to save money—will postpone the day
mendations are the basis for the actual (electronic) written for when the next refill is needed. But a date for when the next
prescription of the drugs issued by the physician, which enables refill is needed cannot be modeled or estimated without unrea-
the patients to pick up the drugs at any Danish pharmacy of their sonable extra assumptions. Instead, such scenarios will present
choice. themselves as one period with sufficient supply followed by a
gap. A patient is defined as persistent when he or she has a
sufficient supply to implement the prescribed dosing regimen
Prescriptions Filled by the Patient with gaps between refills that are smaller than a predefined
Every filled prescription (Rx) is registered with information about number of days (here 180 days). If the patient has been without
the date of purchase, purchased amount of the drug in defined supply for more than the predefined number of days, then we
daily doses (DDDs) [24], ATC code, and the patient’s identity assume that treatment has been discontinued by the patient and
number. Since 1995 this information is stored in the Register of he or she is no longer persistent. This is shown with the red
Medicinal Product Statistics (RMPS) owned by the Danish Health dotted line in Figure 1. Discontinuation may be followed by a later
and Medicines Authority and was made available to us via resumption of treatment, starting the process over again. Treat-
Statistics Denmark. ment can also be discontinued by the physician, and then in
268 VALUE IN HEALTH 17 (2014) 266–274
Time to Acceptance
Initiation Acceptance
Gap Nonpersistent
Persistent Persistent
Discontinuation
Days with sufficient supply to implement dosing regimen
Days without supply
Fig. 1 – Example of a patient’s time line in different states of adherence to medication. The patient is in waiting from the
time the medication is prescribed and until the first Rx, when treatment is initiated. The patient is able to implement
the dosing regimen when he or she has a sufficient supply to cover the daily prescribed dose. Gaps occur when the
patient is without supply of medication. He or she is still persistent, if he or she does not exceed the cutoff value
(here 180 days) for a gap. When the number of consecutive days without the supply of medication exceeds the cutoff
value for the length of a gap, the patient has discontinued treatment and is no longer persistent. At point of second Rx, the
patient resumes treatment, because he or she has a sufficient supply to implement the dosing regimen again. Rx, filled
prescription.
Where the prevalence describes the adherence pattern for the It is hard to believe that a dichotomization of long-term patient
entire population, the incidence rates explain the volatility of the behavior related to adherence to medication (poor or good)
patients’ transitions between states. Empirical incidence rates for provides much useful information. The model we have proposed
selected transitions (indicated with α, β, γ, and μ in Fig. 3) are overcomes the limitations that analyses based on summary
shown in Table 1. statistics face because it uses the time points for transitions
Time to first gap and time to first discontinuation after the between states and differentiates between several types of poor
date of initiation is shown in Figure 5. On comparing metformin adherence: patients who do not accept treatment initially;
with simvastatin, we found that more patients on metformin patients who discontinue early; or patients with a low degree of
commence earlier on a gap than do patients on simvastatin. More implementation, which indicate many or long gaps. This is more
patients on simvastatin discontinue treatment earlier than do useful when identifying which patients or drugs to target for
patients on metformin, regardless of the choice of the cutoff counseling or other types of intervention to improve adherence.
value (50, 100, or 180 days). The multistate model also has the potential for looking into
health outcomes (e.g., long-term diabetes complications) related
to specific patterns of adherence to medication and to analyze
determinants of changes in transition rates and prevalence of the
Discussion
different states over time (socioeconomic factors, medication
complexity, comorbidity, etc.).
Principal Findings If treatment of the chronic disease under study is
We developed a multistate model by defining the possible states characterized either by (frequent) switches between drugs
of a patient, and when transitions between states occur. The or by add-ons of more drugs from the same therapeutic class,
model provides a tool to use prescription data to estimate which is common in T2DM, it would make sense to model the
transition rates between states over time. Thus, changes in entire group of drugs. This can be done by transforming
transition rates and prevalence over time can be estimated on prescribed doses into DDD units and adding up to a total for
several time scales (calendar time, age of the patients, and time the group of drugs. A similar procedure must be used for the
since indication for medication). filled amounts and then the model must be applied as
Adherence to medication has often been reported as a binary shown. Analyses of patients’ health outcomes related to
outcome (poor adherence o80% or good adherence Z80%) [26,27]. their pattern of adherence to medication would benefit from
270 VALUE IN HEALTH 17 (2014) 266–274
100
100
100
Waiting Nonaccepting
Nonpersistent
Gap
80
80
80
60
60
60
40
40
40
With sufficient supply to
implement dosing regimen
20
20
20
Max. length of a gap = 180 days Max. length of a gap = 100 days Max. length of a gap = 50 days
0
0
0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5
100
100
100
Waiting
Nonaccepting
80
80
80
Nonpersistent
Gap
60
60
60
40
40
40
With sufficient supply to
implement dosing regimen
20
20
20
Max. length of a gap = 180 days Max. length of a gap = 100 days Max. length of a gap = 50 days
0
0 1 2 3 4 5 0 1 2 3 4 5 0 1 2 3 4 5
Fig. 4 – Time course of adherence to metformin and simvastatin (prevalence over 5 years). The green area is the prevalence
of patients with a sufficient supply of medication to implement the dosing regimen. The blue area is the prevalence of
patients waiting to fill the first prescription after the medication has been prescribed. The prevalence of patients waiting
stabilizes around 3 to 4 months after the medication has been prescribed. After 1 year, a proportion of the patients (purple
color) are categorized as not accepting treatment. However, some of these do initiate treatment later, narrowing the purple
area. The orange area is the prevalence of the patients who no longer have a sufficient supply of medication available
and thus experience a gap. For simvastatin, an increase in the orange area and a decrease in the green area are seen
after 3 months, followed by a gradual increase in the prevalence of patients with sufficient supply (the second green peak).
This is an illustration of some patients filling the first prescription with medication for 3 months, but managing to
fill the second prescription only after having run out of supply after the first fill. The red area is the prevalence of patients
having discontinued treatment. The size of the area depends on the choice of the cutoff value for the maximum acceptable
length of a gap.
population under investigation, because the person-years in the assume that every Rx lasts a fixed number of days or do require
waiting state are not recorded [25,42]. only a minimum number of refills during a prespecified period of
Studies investigating persistence/possession measures do not time. That may over- or underestimate adherence to medication
necessarily take the actual prescribed doses into account, but [32,42,43].
272 VALUE IN HEALTH 17 (2014) 266–274
Metformin
Commencing a gap α 2.82 (2.77–2.87) Gap With supply 13,449 4,772.0
Discontinuation to γ 0.27 (0.24–0.31) Nonpersistent Gap 224 820.2
nonpersistent
Refilling of medication after a β1 15.46 (15.19–15.73) With supply Gap 12,682 820.2
gap
Refilling of medication after β2 1.29 (1.06–1.51) With supply Nonpersistent 125 97.0
being nonpersistent
Not accepting treatment μ 0.02 (0.02–0.03) Nonaccepting 4 states* 144 6,060.9
Simvastatin
Commencing a gap α 1.41 (1.38–1.44) Gap With supply 6,809 4,833.0
Discontinuation to γ 0.50 (0.45–0.55) Nonpersistent Gap 394 793.2
nonpersistent
Refilling of medication after a β1 7.43 (7.24–7.62) With supply Gap 5,891 793.2
gap
Refilling of medication after β2 1.04 (0.89–1.19) With supply Nonpersistent 183 176.2
being nonpersistent
Not accepting treatment μ 0.06 (0.05–0.06) Nonaccepting 4 states* 379 6,459.7
Note. Incidence rates for number of transitions per person-year from one state to another. Based on a maximum acceptable length of 180 d
for a gap.
* The four states are 1) with supply to implement dosing regimen, 2) a gap, 3) nonpersistent, and 4) waiting.
Generalizability the drug concentration in plasma [11]. For other types of medi-
cation, it will only make sense to operate with a very short
The algorithm requires definition of cutoff values for acceptance
maximum acceptable length of a gap before a patient must be
and gaps. It is outside the scope of this article to discuss
considered as nonpersistent. The choice of cutoff values must
the “correct” choice of the maximum acceptable length of a
always depend on the drugs under study and hence is a clinical
gap before a patient is considered to have discontinued treatment
decision.
and has become nonpersistent. Even rather long gaps may not
The multistate methodology, detailed here, is applicable
be a problem in cases of drugs with a long half-life or forgiveness,
in cases in which detailed information on prescribed and filled
or in cases in which the outcomes of the medication are linked
medication is available at an individual level. Thus, in Scandi-
to long-term medication effects [43]. It is known that the carry-
navian countries, Scotland, and Healthcare Management
over effect of a drug in many cases lags well behind changes in
2500
2500
2000
2000
1500
1000
1000
500
0 1 2 0 1 2
Fig. 5 – Time to first gap and first discontinuation after date of initiation. Time to discontinuation is shown in three different
versions using a maximum acceptable length of a gap of 50, 100, and 180 days, respectively.
VALUE IN HEALTH 17 (2014) 266–274 273
Organizations [44], it would be possible to conduct similar [16] Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing
analyses. Danish health care professionals may use the Medicine and defining adherence to medications. Br J Clin Pharmacol
2012;73:691–705.
Profile (at https://www.sundhed.dk/sundhedsfaglig/min-side/
[17] Lehane E, McCarthy G. Intentional and unintentional medication
patientdata/medicinprofilen/ [in Danish]) for online calculation non-adherence: a comprehensive framework for clinical
of a specific patient’s adherence to medication, provided the research and practice? A discussion paper. Int J Nurs Stud
patient has consented [45]. Flaws in the Medicine Profile, how- 2007;44:1468–77.
ever, have been reported [46]. [18] Edwards LD, Fox AW, Stonier PD, eds. Principles and Practice of
Pharmaceutical Medicine (3rd ed.). West Sussex: Wiley-Blackwell, 2011.
[19] Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks
and multi-state models. Stat Med 2007;26:2389–430.
[20] International Diabetes Federation. IDF diabetes atlas. Available from:
Future Research http://www.idf.org/diabetesatlas/5e/the-global-burden. [Accessed
This study and WHO’s estimates of a low degree of adherence to September 4, 2013].
[21] Nathan DM, Buse JB, Davidson MB, et al. Medical management of
long-term therapies in general indicate a large potential for hyperglycemia in type 2 diabetes: a consensus algorithm for the
improved health and quality of life among patients with poor initiation and adjustment of therapy—a consensus statement of the
adherence to medication, if identified and helped to improve- American Diabetes Association and the European Association for the
ment of adherence. We will pursue to develop a tool for the Study of Diabetes. Diabetes Care 2009;32:193–203.
[22] Danish Endochrine Society, Institute for Rational Pharmacotherapy,
identification of patients with different types of poor adherence
The Danish College of General Practitioners. Guidelines for type
to medication. Associations between measures of adherence to 2-diabetes [pamphlet]. 2011.
medication based on this model and health outcomes are also to [23] WHO Collaborating Centre for Drug Statistics Methodology.
be investigated. ATC: structure and principles. Available from: http://www.
Sources of financial support: This study has in part been whocc.no/atc/structure_and_principles/. [Accessed September 4,
2013].
funded by The Danish Agency for Science, Technology and [24] WHO Collaborating Centre for Drug Statistics Methodology. DDD:
Innovation (at The Ministry of Science, Innovation and Higher definition and general considerations. Available from: http://www.
Education) and “danmark” sygeforsikring (a mutual health insur- whocc.no/ddd/definition_and_general_considera/. [Accessed
ance company). The funders had no role in study design, data September 4, 2013].
[25] Raebel MA, Carroll NM, Ellis JL, et al. Importance of including early
collection and analysis, decisions to publish, or preparation of the
nonadherence in estimations of medication adherence. Ann
manuscript. Pharmacother 2011;45:1053–60.
[26] Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the
association between adherence to drug therapy and mortality. BMJ
R EF E R EN CE S
2006;333(7575):15.
[27] DiMatteo M, Giordani P, Lepper H, Croghan T. Patient adherence and
medical treatment outcomes: a meta-analysis. Med Care
2002;40:794–811.
[1] World Health Organization, Sabete E, ed. Adherence to Long-Term [28] Johannesdottir SA, Mægbæk ML, Hansen JG, et al. Correspondence
Therapies: Evidence for Action. Geneva: World Health Organization, between general practitioner-reported medication use and timing of
2003. prescription dispensation. Clin Epidemiol 2012;4:13–8.
[2] Cramer JA. A systematic review of adherence with medications for [29] Christensen A, Christrup L, Fabricius P, et al. The impact of an
diabetes. Diabetes Care 2004;27:1218–24. electronic monitoring and reminder device on patient compliance with
[3] Vermeire E, Hearnshaw H, van Royen P, Denekens J. Patient adherence antihypertensive therapy: a randomized controlled trial. J Hypertens
to treatment: three decades of research. A comprehensive review. J Clin 2010;28:194–200.
Pharm Ther 2001;26:331–42. [30] Blaschke T, Osterberg L, Vrijens B, Urquhart J. Adherence to
[4] World Health Organization, Sabete E, ed. Adherence to Long-Term medications: insights arising from studies on the unreliable link
Therapies: Policy for Action. Meeting Report. Geneva: World Health
between prescribed and actual drug dosing histories. Ann Rev
Organization 2001.
Pharmacol Toxicol 2012;52:275–301.
[5] Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic
[31] Steiner J, Prochazka A. The assessment of refill compliance using
medication adherence and glycemic control in managed care. Am J
pharmacy records: methods, validity and applications. J Clin Epidemiol
Manag Care 2008;14:71–5.
1997;50(1):105–16.
[6] Schectman J, Nadkarni M, Voss J. The association between diabetes
[32] Caetano PA, Lam JMC, Morgan S. Toward a standard definition and
metabolic control and drug adherence in an indigent population.
measurement of persistence with drug therapy: examples from research
Diabetes Care 2002;25:1015–21.
on statin and antihypertensive utilization. Clin Ther 2006;28:1411–24.
[7] Lau D, Nau DP. Oral antihyperglycemic medication nonadherence and
[33] Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence
subsequent hospitalization among individuals with type 2 diabetes.
with chronic medication assessed from a pharmacy database was
Diabetes Care 2004;27:2149–53.
[8] Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause influenced by method of calculation. J Clin Epidemiol 2006;59(1):11–7.
preventable admissions to hospital? A systematic review. Br J Clin [34] Mantel-Teeuwisse A, Klungel O, Verschuren W, et al. Comparison of
Pharmacol 2007;63:136–47. different methods to estimate prevalence of drug use by using
[9] Ho P, Rumsfeld J, Masoudi F, et al. Effect of medication nonadherence pharmacy records. J Clin Epidemiol 2001;54:1181–6.
on hospitalization and mortality among patients with diabetes [35] Cramer JA, Benedict Á, Muszbek N, et al. The significance of compliance
mellitus. Arch Intern Med 2006;166:1836. and persistence in the treatment of diabetes, hypertension and
[10] Jha AK. Greater adherence to diabetes drugs is linked to less hospital dyslipidaemia: a review. Int J Clin Pract 2007;62:76–87.
use and could save nearly $5 billion annually. Health Aff [36] Donnan P, MacDonald TM, Morrist AD. Adherence to prescribed oral
2012;31:1836–46. hypoglycaemic medication in a population of patients with type 2
[11] Urquhart J. Variable compliance and persistence with prescribed drug diabetes: a retrospective cohort study. Diabet Med 2002;19:279–84.
dosing regimens: implications for benefits, risks, and economics of [37] Osterberg L, Blaschke T. Drug therapy: adherence to medication. N Engl
pharmacotherapy. In: Strom BL, ed., Pharmacoepidemiology (4th ed.). J Med 2005;353:487–97.
John Wiley & Sons, Ltd; 2005:767–89. [38] Gadkari AS, Pedan A, Gowda N, McHorney CA. Survey nonresponders to
[12] DiMatteo M. Variations in patients’ adherence to medical a medication-beliefs survey have worse adherence and persistence to
recommendations: a quantitative review of 50 years of research. Med chronic medications compared with survey responders. Med Care
Care 2004;42:200–9. 2011;49:956–61.
[13] Schneeweiss S, Avorn J. A review of uses of health care utilization [39] Hansen RA, Kim MM, Song L, et al. Comparison of methods to assess
databases for epidemiologic research on therapeutics. J Clin Epidemiol medication adherence and classify nonadherence. Ann Pharmacother
2005;58:323. 2009;43(3):413–22.
[14] Cramer JA. Medication compliance and persistence: terminology and [40] Hamilton RA, Briceland LL. Use of prescription-refill records to assess
definitions. Value Health 2008;11:44–7. patient compliance. Am J Hosp Pharm 1992;49:1691–6.
[15] Peterson A, Nau D, Cramer J, et al. A checklist for medication [41] Zhang Q, Zhao C, Davies M, et al. Compliance and persistence with
compliance and persistence studies using retrospective databases. concomitant statin and oral antihyperglycemic therapy. Am J Manag
Value Health 2007;10:3–12. Care 2011;17:746–52.
274 VALUE IN HEALTH 17 (2014) 266–274
[42] Evans CD, Eurich DT, Remillard AJ, et al. First-fill medication [45] Andersen LS, Kjeldsen LJ, Haugbølle LS. Anvendelighed af den
discontinuations and nonadherence to antihypertensive therapy: an personlige elektroniske medicinprofil til vurdering af komplians [in
observational study. Am J Hypertens 2012;25:195–203. Danish] [Suitability of the Personal Electronic Medication profile for
[43] Greevy RA, Huizinga MM, Roumie CL, et al. Comparisons of persistence
estimation of medication compliance]. Ugeskr Læger 2009;171
and durability among three oral antidiabetic therapies using electronic
(11):899–903.
prescription-fill data: the impact of adherence requirements and
[46] Harbig P, Barat I, Lund Nielsen P, Damsgaard EM. Instantaneous
stockpiling. Clin Pharmacol Ther 2011;90:813–9.
[44] Singer SR. EMR-based medication adherence metric markedly detection of nonadherence: quality, strength, and weakness of an
enhances identification of nonadherent patients. Am J Manag Care electronic prescription database. Pharmacoepidemiol Drug Saf
2012;18:e372–7. 2012;21:323–8.